Maine LD178 prohibits health plans from requiring patients with advanced metastatic cancer to fail a different drug before covering an FDA-approved.
Maine LD178 amends state law to ensure that health plans covering advanced metastatic cancer and its associated conditions cannot mandate that patients fail to respond to another drug or prove a history of failure with another drug before covering an FDA-approved treatment. This applies only to drugs that align with best practices, are supported by evidence-based literature, and are FDA-approved. The bill aims to expedite access to necessary treatments for patients with advanced metastatic cancer.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.